Medigene Past Earnings Performance
Past criteria checks 0/6
Medigene has been growing earnings at an average annual rate of 12.1%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 17% per year.
Key information
12.1%
Earnings growth rate
12.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 17.0% |
| Return on equity | -76.8% |
| Net Margin | -268.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Medigene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 6 | -16 | 9 | 12 |
| 30 Sep 23 | 8 | -23 | 9 | 11 |
| 30 Jun 23 | 9 | -29 | 8 | 10 |
| 31 Mar 23 | 20 | -19 | 9 | 9 |
| 31 Dec 22 | 31 | -8 | 10 | 8 |
| 30 Sep 22 | 31 | 1 | 10 | 8 |
| 30 Jun 22 | 31 | 10 | 10 | 9 |
| 31 Mar 22 | 21 | 0 | 8 | 10 |
| 31 Dec 21 | 10 | -10 | 7 | 11 |
| 30 Sep 21 | 10 | -16 | 7 | 14 |
| 30 Jun 21 | 9 | -22 | 7 | 17 |
| 31 Mar 21 | 8 | -25 | 8 | 20 |
| 31 Dec 20 | 8 | -29 | 9 | 22 |
| 30 Sep 20 | 9 | -25 | 9 | 23 |
| 30 Jun 20 | 9 | -23 | 8 | 23 |
| 31 Mar 20 | 10 | -21 | 8 | 23 |
| 31 Dec 19 | 11 | -20 | 8 | 23 |
| 30 Sep 19 | 9 | -23 | 8 | 20 |
| 30 Jun 19 | 9 | -23 | 8 | 19 |
| 31 Mar 19 | 8 | -19 | 8 | 18 |
| 31 Dec 18 | 8 | -21 | 8 | 17 |
| 30 Sep 18 | 8 | -18 | 8 | 17 |
| 30 Jun 18 | 8 | -16 | 7 | 16 |
| 31 Mar 18 | 8 | -16 | 8 | 16 |
| 31 Dec 17 | 8 | -16 | 8 | 15 |
| 30 Sep 17 | 8 | -14 | 9 | 15 |
| 30 Jun 17 | 8 | -17 | 10 | 14 |
| 31 Mar 17 | 8 | -12 | 10 | 13 |
| 31 Dec 16 | 7 | -9 | 10 | 12 |
| 30 Sep 16 | 6 | -8 | 10 | 10 |
| 30 Jun 16 | 7 | -7 | 8 | 9 |
| 31 Mar 16 | 7 | -11 | 8 | 9 |
| 31 Dec 15 | 7 | -13 | 8 | 9 |
| 30 Sep 15 | 11 | -11 | 7 | 8 |
| 30 Jun 15 | 11 | -9 | 7 | 8 |
| 31 Mar 15 | 13 | -7 | 7 | 8 |
| 31 Dec 14 | 13 | -6 | 7 | 7 |
| 30 Sep 14 | 10 | -8 | 8 | 7 |
| 30 Jun 14 | 9 | -7 | 8 | 7 |
| 31 Mar 14 | 8 | -9 | 8 | 6 |
| 31 Dec 13 | 8 | -10 | 8 | 7 |
| 30 Sep 13 | 8 | -17 | 8 | 7 |
| 30 Jun 13 | 7 | -18 | 8 | 7 |
Quality Earnings: MDG1 is currently unprofitable.
Growing Profit Margin: MDG1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MDG1 is unprofitable, but has reduced losses over the past 5 years at a rate of 12.1% per year.
Accelerating Growth: Unable to compare MDG1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MDG1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: MDG1 has a negative Return on Equity (-76.79%), as it is currently unprofitable.